Loading...
skip to Main Content

This page offers you with an array of useful resources related to COVID-19 and the liver, including articles, accounts from healthcare professionals, calls for abstracts, and statements.
You are welcome to send suggestions of materials to include to us at marcomms@easloffice.eu

EASL webinars

EASL has launched a series of webinars relating to COVID-19. The participants are world-renowned scientists and clinicians that discuss and share their knowledge about the latest developments of the virus.

EASL-WHO webinar on COVID-19 and the liver

Don’t miss this special webinar on COVID-19 and the liver organised by EASL and the World Health Organization (WHO).

Listen to a panel of leading international experts and clinicians in hepatology and virology presenting the latest information on the COVID-19 pandemic, the WHO response, and how the pandemic is affecting the care of people with liver disease and viral hepatitis, both from a clinical and public health perspective. Then hear from frontline clinicians and programme managers from different countries on their experiences in the COVID-19 national response, and in managing the impact on hepatitis services during the current crisis. Viewers submitted their questions from around the world. You can read the Q&A, with expert answers.

EASL Campus series of webinars on COVID-19 and the liver

Limited knowledge on COVID-19 has evidenced the importance of sharing up-to-date information. Working with world-renowned experts, EASL has launched a series of open-access webinars relating to COVID-19 and the liver. Watch the webinars and stay tuned for more.

1. Virological Aspects of COVID-19
2. Viral markers and the diagnosis of COVID-19
3. Viral testing and the immune response to COVID-19

EASL, ESOT-ELITA and ILTS joint webinar

A joint webinar on the impact of COVID-19 on liver transplantation. ESOT-ELITA, EASL and ILTS speakers discuss the effects of the pandemic on liver transplantation in Europe and in the United States as well as the response of medical societies in regard to education.

Watch the COVID-19 & liver transplantation webinar.

Testimonials on dealing with the public health crisis

EASL Viewpoints are testimonials, interviews, and videos from healthcare professionals sharing life from the frontlines, across Europe.

In their testimonials, hepatologists, liver nurses, researchers, and academics tell how their working life has been affected by COVID-19 and what might be to come.

France, Italy, Portugal, Sweden, the UK… and more to come – watch the videos, read the interviews, and get to meet members of the hepatology community.

Access EASL Viewpoints

COVID-19 related papers from the Journal of Hepatology and JHEP Reports

The “EASL COVID-19 article collection” houses articles dealing with COVID-19 and the liver published in EASL’s two journals, Journal of Hepatology and JHEP Reports. This initiative aims at facilitating access to research that can be critically relevant for the treatment of liver patients during the pandemic.

View the EASL COVID-19 papers

News from the EASL supported COVID-Hep registry

Press release, 21/05/2020

A new international study has found increased mortality rates from COVID-19 among people with chronic liver disease and cirrhosis and has called for patients with worsening liver function to be tested for coronavirus.

The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry (the EASL supported COVID-hep registry, see below) to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19. Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95% of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called decompensated cirrhosis had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.

Read more.

The EASL supported COVID-Hep registry was launched at the University of Oxford, UK on 23 March 2020. The registry is collecting data on patients, with liver disease at any stage or liver transplants, that have also developed laboratory-confirmed COVID-19. On 21 May, a study based on the first 152 consecutive submissions was published in the Journal of Hepatology.

As of 22 September, data collected (combined with data from SECURE-cirrhosis who are covering the Americas, China, Japan, and Korea) has grown to 1,335 submissions, constituting 1,149 cases and 232 deaths; 545 with cirrhosis
and 170 liver transplant recipients. Browse the weekly updates and downloadable reports.

To find out more or make a submission, visit COVID-Hep. You can also request updates by email.

Read more

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper

EASL-ESCMID Position Paper: a review, six months into the pandemic

Six months into the COVID-19 pandemic, an article has been published in JHEP Reports to provide guidance for physicians involved in the care of patients with chronic liver disease. It serves as an update, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible.

EASL-ESCMID-covid-statement

In response to the COVID-19 pandemic, EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position Paper providing recommendations for clinicians on caring for patients with liver diseases and for liver transplant recipients. The joint Position Paper also provides a flowchart and an overview of current treatment options, to help clinicians with decision-making during this resource-strapped time.

Webinars on COVID-19 and the liver

Apasl-logo

APASL COVID-19 Webinars, a series of seven episodes, draws on the experience of doctors from the Asian Pacific who faced COVID-19 first.

Register here for APASL webinars.

aasldlogosquare

Discover here all the AASLD COVID-19 RESOURCES

Journal of Hepatology call for papers on COVID-19

The outbreak of COVID-19 (coronavirus) is of great concern and a considerable challenge for practitioners and public health authorities. Following the initiative of other leading scientific journals, we believe that it is timely, important, and appropriate to share with our Journal of Hepatology readers, as soon as possible, all information available on the possible impact of the infection on the liver and on patients with liver diseases.

We therefore invite authors to send their original data on these topics. We will provide authors with a rapid evaluation and, if their articles are accepted, free access to their content. Of course, as an obligation to our community, we will ensure the same high standards of scientific review for these articles.

Read more

External resources on COVID-19

online-booking-exhibition-space

Public health resources

European Centre for Disease Prevention and Control: COVID-19
European Centre for Disease Prevention and Control: today’s data on geographic distribution of COVID-19 cases worldwide
European Commission: Coronavirus response
European Commission: Public health
European Medicines Agency: Coronavirus disease (COVID-19)
World Health Organization: Coronavirus disease (COVID-19) outbreak
World Health Organization: Coronavirus disease (COVID-19) Pandemic 
World Health Organization: Q&A on coronaviruses (COVID-19)

Curated resources

British Medical Journal: Coronavirus (covid-19): Latest news and resources
Cell Press: COVID-19 Resource Hub
The Lancet: COVID-19 Resource Centre
New England Journal of Medicine: Coronavirus (Covid-19)
Science: Coronavirus: Research, Commentary, and News

COVID-19 and the liver

The Lancet: COVID-19 and the liver: little cause for concern
The Lancet: Liver injury in COVID-19: management and challenges
Wiley Online, Liver International: Liver injury during highly pathogenic human coronavirus infections

Open access scientific articles

Cell.com: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Journal of Clinical Microbiology: The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options
Nature: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus
Nature: Epidemiological data from the COVID-19 outbreak, real-time case information
Nature: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

BioMed Alliance submits Joint Statement to EU leaders, as COVID-19 threatens medical associations

biomed-alliance-cover

Subsequent to the disruption caused by the COVID-19 pandemic, EASL and 32 other leading European medical associations – together forming the Biomedical Alliance in Europe (BioMed Alliance) – have submitted a joint statement to EU leaders.

Read more 

Latest news from the community

How do #sarcopenia & #frailty impact on later stages of #liver disease? https://easl.eu/press-release/frailty-sarcopenia/ Read this study by Dr Linge et al drawing on a large UK #biobank imaging study, just published in @JHEP_Reports @EASLedu

Discover a collection of the most important articles, based on citations, from @JHepatology and @JHEP_Reports, dedicated to #COVID19 and the #liver. See the collection here https://easl.eu/covid-19-and-the-liver/ @massimoiava @tom_marjot @EleanorBarnesOx @ColmeneroJordi @julie_lucifora

Please help us raise the profile of PSC today on #PSCAwarenessDay 🙏

🤷‍ A complex liver disease
😩 Daily symptoms like fatigue, pain & itch
👨‍👩‍👧 Can affect anyone at any age
❌ No medical treatment

#LetsBeatPSC #PSCSupport #PSCAware @EASLedu @EuropeLiver @LiverPatients

🎧NEW CONTENT for #LiverCancerAwarenessMonth! Listen to a podcast with @massimoiava answering key questions on liver cancer raised by @LiverPatients & @PSCSupportUK. Listen here: https://easl.eu/liver-cancer-awareness/ & share the news! @EASLedu @EuropeLiver @JHepatology @ma5RN @policlinicoMI

Check this snapshot by @JHepatology 🔥🔥👇👇
#UEGambassador #livertwitter #LiverDisease #GITwitter @my_ueg @KM_Pawlak @drdalbir @stevenbollipo @RodriguezParra_ @RobertoSimonsMD @ChahalPrabhleen @SanchezLunaMD @EASLedu @BilalMohammadMD @DCharabaty @RashidLui @SunilAminMD https://twitter.com/JHepatology/status/1321023115669966853

Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma https://bit.ly/3oywFNz #LiverAwarenessMonth #LiverCancerAwarenessMonth

In Press | Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in #NAFLD. #openaccess at https://bit.ly/3e5O3EP #sarcopenia #frailty

Back To Top